Tivumecirnon

Cat. No.: HY-148494

CAS No.: 2174938-78-2

Molecular Formula: $C_{24}H_{27}Cl_2F_3N_6O$

Molecular Weight: 543.41

Target: CCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (184.02 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.8402 mL	9.2012 mL	18.4023 mL
	5 mM	0.3680 mL	1.8402 mL	3.6805 mL
	10 mM	0.1840 mL	0.9201 mL	1.8402 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (4.60 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Tivumecirnon (FLX475) is an orally active CCR4 antagonist that blocks regulatory T cells from entering the tumor microenvironment, thereby reducing their interference with effective anti-tumor immune responses. Tivumecirnon has antitumor activity[1][2].

REFERENCES

[1]. Hilary Plake BECK, et al. Chemokine receptor modulators and uses thereof. WO2018022992.

[2]. Adam Grant, et al. Abstract 2485: A combined mregDC and Treg signature associates with antitumor efficacy of CCR4 antagonist tivumecirnon FLX475. Cancer Res 15 March 2024; 84 (6_Supplement): 2485.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA